Referred to the House Committee on Energy and Commerce.
This bill directs HHS, through NIEHS, to award research grants studying effects of personal care products that contain endocrine-disrupting chemicals on the female reproductive system. It requires five-yearly public reports listing safe and harmful products, outlines disparities in access, suggests strategies to expand FDA regulatory authority, and provides state grants for investigation and public awareness campaigns.
Liberals emphasize health, disparities, and regulatory follow-through
Relative to its intended legislative type, this bill functions primarily as a research/ reporting-authority measure with administrative assignment to NIEHS and state grant components.
This bill directs HHS, through NIEHS, to award research grants studying effects of personal care products that contain endocrine-disrupting chemicals on the female reproductive system.
It requires five-yearly public reports listing safe and harmful products, outlines disparities in access, suggests strategies to expand FDA regulatory authority, and provides state grants for investigation and public awareness campaigns.
Modest chances: technocratic, limited scope, and nonbinding tools help; lack of appropriations and possible industry pushback reduce odds.
Relative to its intended legislative type, this bill functions primarily as a research/ reporting-authority measure with administrative assignment to NIEHS and state grant components. It clearly states the problem and reporting requirements, but it lacks critical implementation details, funding provisions, and protections that would be expected to operationalize the grant programs and public product listings.
Liberals emphasize health, disparities, and regulatory follow-through
These are examples from the analysis, not a ranked list of the most-affected groups.
Liberals emphasize health, disparities, and regulatory follow-through
Likely supportive because it focuses on women’s reproductive health, environmental health, and disparities in product safety.
May criticize the bill for lacking mandated regulatory action and for unspecified funding levels.
Generally favorable to using federal research grants to inform policy, while emphasizing evidence, cost control, and clear implementation.
Will seek safeguards to prevent politicized product lists and unnecessary regulatory disruption.
Skeptical of federal expansion into cosmetics regulation and of government-driven product labeling.
Might accept narrowly scoped research grants but opposes recommendations that enlarge FDA authority or harm small businesses.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Modest chances: technocratic, limited scope, and nonbinding tools help; lack of appropriations and possible industry pushback reduce odds.
The bill has not accumulated any surfaced votes yet.
Liberals emphasize health, disparities, and regulatory follow-through
Modest chances: technocratic, limited scope, and nonbinding tools help; lack of appropriations and possible industry pushback reduce odds.
Relative to its intended legislative type, this bill functions primarily as a research/ reporting-authority measure with administrative assignment to NIEHS and state grant components. It clearly states the problem and r…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.